MoreLatest news
June 2009
Glybera(TM) Shows Long-Term Health Benefits
read more
read more
May 2009
AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria
read more
read more
May 2009
AMT issues business update for first quarter 2009
read more
read more
May 2009
AMT Starts Preregistration Trial for GlyberaTM
read more
read more
February 2009
Amsterdam Molecular Therapeutics Reports Full Year Results 2008
read more
read more
February 2009
AMT to Release Full Year 2008 Results on February 24, 2009
read more
read more
January 2009
AMT: Glybera(R) Lowers Pancreatitis Incidence Significantly
read more
read more
January 2009
AMT CEO Ronald Lorijn Steps Down
read more
read more
November 2008
Dr. Ronald Lorijn Opened Trading Day NYSE Euronext Amsterdam
read more
read more
October 2008
AMT intends to incorporate additional data to its Marketing Authorization Dossier for Glybera®
read more
read more
